-
1 month ago | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Emma Guttman-Yassky
Key takeaways: 32.8% of rocatinlimab-treated patients achieved the co-primary endpoint of EASI 75 by week 24. 19.3% reached the other co-primary endpoint, defined as a validated IGA-AD score of 0 or 1 by week 24.
-
Dec 10, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Emma Guttman-Yassky
You've successfully added Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Tremfya (guselkumab) is an interleukin-23 inhibitor. The submissions are supported by clinical and pharmacokinetic data from multiple phase 3 studies.
-
Dec 6, 2024 | 
healio.com | Rebecca Forand |Emma Guttman-Yassky |Kristen Dowd
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio cDermatology Chief Medical Editor, discusses hot topics in the field with leading experts.
-
Nov 7, 2024 | 
healio.com | Joel M. Gelfand |Emma Guttman-Yassky |Kristen Dowd
Read more You've successfully added Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.
-
Aug 12, 2024 | 
healio.com | Victoria Langowska |Shenaz Bagha |Emma Guttman-Yassky
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Tralokinumab normalized expression of AD biomarkers in serum and lesional skin. Tralokinumab improved epidermal pathology and reduced inflammatory mediators and abnormal skin barrier markers.
-
Jul 30, 2024 | 
ascpt.onlinelibrary.wiley.com | Emma Guttman-Yassky |Michael J. Cork |Margitta Worm |Matthew P. Kosloski
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Interleukin-33 (IL-33), a proinflammatory alarmin cytokine released by damaged epithelial tissue cells, initiates and amplifies both type 1 and type 2 inflammatory cascades. IL-33 has been suggested as having a role in atopic dermatitis (AD), a chronic, relapsing type 2 inflammatory disease of the skin. Itepekimab is a novel human IgG4P monoclonal antibody against IL-33, currently in development for chronic obstructive pulmonary disease (COPD).
-
Jul 17, 2024 | 
jamanetwork.com | Andrew Blauvelt |Emma Guttman-Yassky |Charles W. Lynde |Joel Schlessinger
Key PointsQuestion
Is cendakimab efficacious and safe in patients with moderate to severe atopic dermatitis (AD)? Findings
In this randomized clinical trial of 221 patients with moderate to severe AD, treatment with cendakimab was efficacious after 16 weeks, demonstrating improvements in skin clearance, pruritus, and the extent and severity of AD compared with placebo. Cendakimab was generally safe and well-tolerated.
-
Jun 23, 2024 | 
onlinelibrary.wiley.com | Michael Diaz |Ross O'Hagan |Jasmine T. Tran |Emma Guttman-Yassky
No abstract is available for this article. References 1, , , , , , et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol. 2020; 182(6): 1331–1342. https://doi.org/10.1111/bjd.18643 2, , , . Disseminated bullous impetigo and atopic dermatitis: case series and literature review. Pediatr Dermatol. 2020; 37(1): 103–108. https://doi.org/10.1111/pde.14032 3, , , , , , et al.
-
Jun 1, 2024 | 
sciencedirect.com | Camille Rothenberg-Lausell |Emma Guttman-Yassky |Joshua Wollam |Veena Viswanath
Supported by the (grants to N.J.N. and M.B.R.), as well as by , , and (honoraria to N.J.N.). Disclosure of potential conflict of interest: N. J. Nassikas reports receiving payment from Industrial Economics, Inc, unrelated to the submitted work. M. B. Rice reports receiving payments from the Conservation Law Foundation unrelated to the submitted work. The remaining author declares that he has no relevant
-
May 31, 2024 | 
onlinelibrary.wiley.com | Mia-Louise Nielsen |Christoph Schlapbach |Emma Guttman-Yassky |Jonathan I. Silverberg
DATA AVAILABILITY STATEMENT Outputs from additional analyses are available upon reasonable request. Raw data are not available due to data protection rights.
